梁洋 职务：血液肿瘤科科主任
职称：主诊教授、医学博士、研究员、博士生导师、华南肿瘤学国家重点实验室血液肿瘤课题组PI
专长：白血病、骨髓瘤、MDS、淋巴瘤等恶性血液肿瘤的精准诊断治疗；包括血液系统肿瘤的分子分层诊断与精准标准化治疗，及对标国际标准方案的血液肿瘤的同质化诊治管理。

主要简介 详细介绍 预约挂号

教育背景：
　　1998年获天津医科大学医学系医学学士学位
　　2004年获青岛大学医学院医学硕士学位
　　2007年获上海交通大学医学院瑞金医院上海血液研究所博士学位
留学经历：
　　2011-2016年耶鲁大学医学院肿瘤中心内科部血液系博士后，从事骨髓增生异常综合征发病机制及靶向治疗研究。在Cancer Cell等高水平同行评议专业杂志发表多篇临床及科研文章。

工作经历：
　　2011- 2016：耶鲁大学医学院肿瘤中心内科部血液系博士后，师从国际血液肿瘤著名专家，血液系系主任Halene教授，主攻骨髓增生异常综合征（MDS）发病机制与靶向治疗。
　　2004-2007：上海交通大学医学院上海血液学研究所博士，师从原国家卫生部长，现全国人大副委员长陈竺院士，主攻恶性血液肿瘤的精准诊治。
　　
科研成就：
　　主要研究方向为恶性血液病的精准治疗及发病机制研究 。目前以通讯作者及第一作者身份在Cancer Cell, Blood, Clinical Cancer Research, Leukemia, PNAS, British Journal of Haematology等国际一流专业刊物发表系列临床及科研文章； 累计引用次数1600余次。同时为Nature旗下子刊Leukemia等高水平国际杂志审稿人。



教育背景：
　　1998年获天津医科大学医学系医学学士学位
　　2004年获青岛大学医学院医学硕士学位
　　2007年获上海交通大学医学院瑞金医院上海血液研究所博士学位
留学经历：
　　2011-2016年耶鲁大学医学院肿瘤中心内科部血液系博士后，从事骨髓增生异常综合征发病机制及靶向治疗研究。在Cancer Cell等高水平同行评议专业杂志发表多篇临床及科研文章。

工作经历：
　　2011- 2016：耶鲁大学医学院肿瘤中心内科部血液系博士后，师从国际血液肿瘤著名专家，血液系系主任Halene教授，主攻骨髓增生异常综合征（MDS）发病机制与靶向治疗。
　　2004-2007：上海交通大学医学院上海血液学研究所博士，师从原国家卫生部长，现全国人大副委员长陈竺院士，主攻恶性血液肿瘤的精准诊治。
　　
科研成就：
　　主要研究方向为恶性血液病的精准治疗及发病机制研究 。目前以通讯作者及第一作者身份在Cancer Cell, Blood, Clinical Cancer Research, Leukemia, PNAS, British Journal of Haematology等国际一流专业刊物发表系列临床及科研文章； 累计引用次数1600余次。同时为Nature旗下子刊Leukemia等高水平国际杂志审稿人。

【代表性论著】
1. Yun Wang, Yan-yu Cai, Tobias Herold, Run-cong Nie, Yu Zhang, Robert Peter Gale, Klaus H. Metzeler, Yun Zeng, Shun-qing Wang, Xue-yi Pan, Tong-hua Yang, Yuan-bin Wu, Qing Zhang, Zhi-jun Wuxiao, Xin Du, Zhi-wei Liang, Yong-zhong Su, Jing-bo Xu, Yong-qing Wang, Ze-lin Liu, Jian-wei Wu, Xiong Zhang, Bing-yi Wu, Ruo-zhi Xiao, San-bin Wang, Jin-yuan Li, Pei-dong Chi, Qian-yi Zhang, Si-liang Chen, Zhe-yuan Qin, Xin-mei Zhang, Na Zhong, Wolfgang Hiddemann, Qi-fa Liu, Bei Zhang, and Yang Liang. An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy. Clinical Cancer Research. 2020 Dec 1. doi: 10.1158/1078-0432.CCR-20-3417. Online ahead of print. PMID: **
2. Justin Taylor, Xiaoli Mi, Khrystyna Dilai North, Moritz Binder, Alexander Penson, Terra L Lasho, Katherine Knorr, Michael Haddadin, Bo Liu, Joseph Pangallo, Salima Benbarche, Daniel Howard Wiseman, Ayalew Tefferi, Stephanie Halene, Yang Liang, Mrinal M Patnaik, Robert K Bradley, Omar Abdel-Wahab. Blood 2020 Jul 8; blood.. doi: 10.1182/blood.. Online ahead of print.
3. Huan Li, Chongxiang Chen, Fang Hu, Jiaojiao Wang, Qingyu Zhao, Robert Peter Gale, Yang Liang. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV2, SARS-CoV or MERS-CoV infection: a systematic review and meta-analysis. Leukemia 2020 Jun;34(6):1503-1511. doi: 10.1038/s41375-020-0848-3. Epub 2020 May 5.
4. Yang Liang, Toma Tebaldi, Kai Rejeski, Poorval Joshi, Giovanni Stefani, Ashley Taylor, Yuanbin Song, Radovan Vasic, Jamie Maziarz, Kunthavai Balasubramanian, Anastasia Ardasheva, Alicia Ding, Alessandro Quattrone, Stephanie Halene. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia 2018 Jun 1. doi: 10.1038/s41375-018-0152-7. [Epub ahead of print]
5. Eunhee Kim, Janine O. Ilagan, Yang Liang, Gerrit M. Daubner, Stanley Lee, Aravind Ramakrishnan, Yue Li, Young Rock Chung, Jean-Baptiste Micol, Michele Murphy, Hana Cho, Min-Kyung Kim, Ahmad S. Zebari, Silvia Buonamic, Peter Smith, H. Joachim Deeg, Camille Lobry, Iannis Aifantis, Yorgo Modis, Frederic H.-T. Allain, Stephanie Halene, Robert K. Bradley, Omar Abdel-Wahab. SRSF2 mutations impair hematopoiesis and alter exon recognition. Cancer Cell 2015 May 11; 27(5):617-30. doi: 10.1016/j.ccell.2015.04.006.
6. Yang Liang, Lin-Hai Yang, Hui Jiang, Xiao-Jun Yuan, Li-Rong Sun, Jing-Yan Tang, Ning-Ling Wang. Treatment outcome of young age children with acute lymphoblastic leukemia: achievements and directions implied from Shanghai Children’s Medical Center based SCMC-ALL-2005 protocol. British Journal of Haematology 2015 Apr; 169(2):267-77. doi: 10.1111/bjh.13288.
7. San-Bin Wang, Li Li, Xinhua Pan, Deng-Ming Hu, Li-Hui Peng, Lin Liu, Zheng-Jun Xie, Bo Yin, Xiao-Juan Sun, Jing Yu, Yang Liang. Engraftment of heavily transfused patients with severe aplastic anemia with a fludarabine-based regimen. Clinical Transplantation 2013 Mar-Apr; 27(2):E109-15. doi: 10.1111/ctr.12061.
8. Tao Zhen, Chuan-Feng Wu, Ping Liu, Hai-Yan Wu, Guang-Biao Zhou, Ying Lu, Jian-Xiang Liu, Yang Liang, Keqin Kathy Li, Yue-Ying Wang, Yin-Yin Xie, Miao-Miao He, Huang-Ming Cao, Wei-Na Zhang, Li-Min Chen, Kevin Petrie, Sai-Juan Chen, Zhu Chen. Targeting of AML1-ETO in t(8;21) Leukemia by Oridonin Generates a Tumor Suppressor–Like Protein. Science Translational Medicine 2012 Mar 28;4(127):127ra38. doi: 10.1126/scitranslmed.**.
9. Yue-Ying Wang, Li-Juan Zhao, Chuan-Feng Wu, Ping Liu, Lin Shi, Yang Liang, Shu-Min Xiong, Jian-Qing Mia, Zhu Chen, Ruibao Ren, Sai-Juan Chen, C-KIT mutation cooperates with full length AML1-ETO to induce acute myeloid leukemia in mice. Proceedings of the National Academy of Sciences 2011 Feb 8; 108(6):2450-5. doi: 10.1073/pnas..
10. Bo Jiao, Chuan-Feng Wu, Yang Liang, Hai-Min Chen, Shu-Min Xiong, Bing Chen, Jing-Yi Shi, Yue-Ying Wang, Jing-Han Wang, Yu Chen, Jun-Min Li, Long-Jun Gu, Jing-Yan Tang, Zhi-Xiang Shen, Bai-Wei Gu, Wei-Li Zhao, Zhu Chen and Sai-Juan Chen. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 2009 Sep;23(9):1598-604. doi: 10.1038/leu.2009.104.
11. Lan Wang, Guang-Biao Zhou, Ping Liu, Jun-Hong Song, Yang Liang, Xiao-Jing Yan, Fang Xu, Bing-Shun Wang, Jian-Hua Mao, Zhi-Xiang Shen, Sai-Juan Chen, and Zhu Chen. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proceedings of the National Academy of Sciences 2008 Mar 25; 105(12):4826-31. doi: 10.1073/pnas..
主要国际学术会议：
多次受邀在代表国际最高水平的美国血液学年会等专业会议中，就恶性血液肿瘤的诊治进行大会发言与会议壁报交流。
2020 American Society of Hematology (ASH) 61th Annual Meeting
壁报交流: An Accurate Prognostic Survival Model of Survival Based on Expression of Genes Involved in Plasma Cell Metabolism
壁报交流: An Immune Score Model of the Bone Marrow Micro-Environment Predicts Survival in Chronic Lymphocytic Leukaemia
2019 St. Jude-VIVA-NCMC Pediatric Hematology/Oncology Forum
大会发言: Pathogenesis of MDS and Treatment Update
2019 American Society of Hematology (ASH) 61th Annual Meeting
大会发言: Identification of an Immune Risk Score to Predict the Prognosis of Acute Myeloid Leukemia
壁报交流 (成就奖): A Distinct Metabolic Signature in DNMT3A-Mutated Leukemia
2018 American Society of Hematology (ASH) 60th Annual Meeting
壁报交流: A Refined Regimen for Maximally Eliminating Early Life-Threatening Complications for Patients with High -Risk Acute Promyelocytic Leukemia.
2017 American Society of Hematology (ASH) 59th Annual Meeting
壁报交流: A Cocktail Approach to Maximally Eliminating Early Mortality of Acute Promyelocytic Leukemia Patients.
壁报交流: Monitoring MRD Guided Treatment Outcome of Adult Patients with Acute Lymphoblastic Leukemia Using ALL-BFM95 Based Protocol.
壁报交流: Treatment Outcome of Dasatinib in Combination with Less-Intensive Induction, Homobarringtonie, Cytara bine, G-SCF in Newly Diagnosed Patients with Ph+ALL.
壁报交流: Improved Outcome of Haploidentical Peripheral Blood Stem Cell Transplant Treating Severe Aplastic Anemia.
壁报交流: Targeting Systemic Inflammatory Response Syndrome as Initial Therapy and Oral Arsenic Based Consolidation Regimen for Acute Promyelocytic Leukemia.
2015 American Society of Hematology (ASH) 57th Annual Meeting
大会发言: Integrative genome-wide analysis of RNA binding and splicing reveals complex loss and gain of function alterations by SRSF2 P95 mutations in myelodysplasia
2007 American Society of Hematology (ASH) 49th Annual Meeting
壁报交流: AML1-ETO9a Correlated with C-KIT Overexpression/Mutation and Indicated Poor Disease Outcome in t(8;21) Acute Myeloid Leukemia

学术兼职：
美国血液学协会会员
吴阶平医学基金会精准医学学部副主任委员
亚太医学生物免疫学会血液学分会候任主任委员
中华医学会血液学分会第十一届委员会浆细胞疾病学组委员
中华医学会血液学分会第十一届委员会中西整合医学学组组员
中国老年医学学会血液学分会第一届委员会MDS学术工作委员会委员
广东省高层次引进人才，珠江人才计划，中山大学“****”****


更新时间：2021年2月18日